<div id="readability-page-1"><p>Deutsche Bank  analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG today and set a price target of CHF135.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Papadakis is a 4-star analyst with an average return of <span>3.5%</span> and a 51.26% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG.</p> <p>In addition to Deutsche Bank , Novartis AG also received a Buy from Morgan Stanley’s Thibault Boutherin in a report issued yesterday. However, today, Goldman Sachs maintained a Sell rating on Novartis AG (Six Swiss: NOVN).</p></div>

<p>Deutsche Bank analyst Emmanuel Papadakis has reaffirmed a Buy rating for Novartis AG (NOVN) with a price target of CHF135.00. Papadakis, a 4-star analyst with a 51.26% success rate, also covers other healthcare stocks. Additionally, Morgan Stanley's Thibault Boutherin issued a Buy rating for Novartis AG, while Goldman Sachs maintained a Sell rating on the stock.</p>

Tip Ranks

Novartis AG

NOVARTIS AG

Deutsche Bank AG

AstraZeneca

AstraZeneca PLC

GlaxoSmithKline plc

ROCHE HOLDINGS AG

Roche

Morgan Stanley

Goldman Sachs

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GSK plc Sponsored ADR

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

GS Hldg R

Deutsche Bank  Sticks to Their Buy Rating for Novartis AG (NOVN)